<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="Database, China National Knowledge Infrastructure, Chongqing VIP, Wangfang Data. Literature" exact="screening" post="and data extraction will be independently performed by 2"/>
 <result pre="drug resistance. The mechanism of nucleos (t)ide analogues in the" exact="treatment" post="of CHB is to inhibit viral replication and reduce"/>
 <result pre="fibrosis. This meta-analysis aims to provide a basis for clinical" exact="treatment" post="for CHB, and explore whether KS combined with ETV"/>
 <result pre="will be included. 2.2.2 Types of patients Patients with the" exact="diagnosis" post="of CHB[8]: positive hepatitis B virus surface antigen and/or"/>
 <result pre="group should be treated with ETV alone. The course of" exact="treatment" post="should be &amp;gt;3 months, and if there were other"/>
 <result pre="and analysis 2.4.1 Selection of studies and data extraction Literature" exact="screening" post="and data extraction will be carried out independently by"/>
 <result pre="researcher (QZ). If the required information is incomplete, we will" exact="contact" post="the author to obtain the necessary data. The entire"/>
 <result pre="of bias, or &quot;Unclear risk&quot; of bias. 2.4.3 Measures of" exact="treatment" post="effect The extracted data will be analyzed using the"/>
 <result pre="be conducted if there is a significant heterogeneity (grouped by" exact="treatment" post="duration, dosage form, sample size) and sensitivity analysis will"/>
 <result pre="CHB. In order to provide more references for the clinical" exact="treatment" post="of CHB. Author contributions None. Abbreviations: ALT = alanine"/>
 <result pre="B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite" exact="treatment" post="duration unlikely. J Hepatol2013;58:676–83.23219442 [3]TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis,"/>
 <result pre="duration unlikely. J Hepatol2013;58:676–83.23219442 [3]TerraultNALokASFMcMahonBJet al.Update on prevention, diagnosis, and" exact="treatment" post="of chronic hepatitis B: AASLD 2018 hepatitis B guidance."/>
 <result pre="hepatitis B. Exp Ther Med2017;14:5837–42.29285129 [7]WangYPZhaoWXueRet al.Oxymatrine inhibits hepatitis B" exact="infection" post="with an advantage of overcoming drug-resistance. Antiviral Res2011;89:227–31.21277330 [8]collab:"/>
 <result pre="Society of Infectious Diseases CMA. The guideline of prevention and" exact="treatment" post="for chronic hepatitis B: a 2015 update. J Clin"/>
</results>
